You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Electrochemical Drug Infusion Pump

    SBC: LYNNTECH INC.            Topic: OSD05H01

    The CONOPS for the Expeditionary Medical Support System (EMEDS) is based on practical effectiveness, speed, and efficiency. Key among the tools required by the Air Mobility Command and the Air Combat Command, which are two of the major commands that are part of the United Air Force is a multi-channel intravenous infusion pump capable of delivering fluids that meets the safe-to-fly criteria for all ...

    SBIR Phase II 2019 Department of DefenseDefense Health Agency
  2. Developing Software for Pharmacodynamics and Bioassay Studies

    SBC: TConneX Inc.            Topic: DHP16C001

    Thegoal is to develop asoftwaretool that implementsa novelapproach applicableto fitgeneral pharmacologic, toxicology, or other biomedical data, that mayexhibita non-monotonic dose-responserelationship for which thecurrent parametricmodels fail. Thesoftwareexplores dose-responserelationships using both monotonicand non-monotonicmodels,and estimates theassociated doseresponsecurves,which can further ...

    STTR Phase II 2019 Department of DefenseDefense Health Agency
  3. SBIR TOPIC 97- PHASE II- MINIMALLY INVASIVE TEST FOR CHEMOTHERAPY-INDUCED CARDIOTOXICITY

    SBC: ACCEL DIAGNOSTICS, LLC            Topic: NHLBI

    Cardiovascular toxicityCVTxis a serious short and long term complication of many anti cancer chemotherapeutic regimensZamoranoLancellotti et alIn this PhaseSBIR submission to continue the development and validation of Accel Diagnosticsminimally invasiverapidcost effective and connected blood testthe pScreen CVTx TMfor the early detection and continuous of chemotheropy induced CVTx

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. CNT-Vectored Delivery of mRNA for HIV-Vaccines

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: NIAID

    Developing safe and effective preventives for HIV remains the hope for controlling the global AIDS epidemicRecentlymRNA vaccines have emerged as a promising alternative to conventional vaccine approaches because of their high potencycapacity for rapid developmentpotential for low cost manufactureTo datethere is no effective mRNA protective vaccine for HIVand the need for one is vastDespite the adv ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Rapid, Accurate Point-of-Care Test for Gonorrhea and Determination of Antimicrobial Susceptibility

    SBC: AI BIOSCIENCES, INC.            Topic: NIAID

    Antimicrobial resistant gonorrheacaused by Neisseria gonorrhoeaeNGhas become an urgent threat for global public healthThe goal of this project is to develop a one hour point of care diagnosticPOCtest capable of identifying NGand determining the infecting strain s susceptibility to antibioticsAI Biosciences plans to achieve this goal by expanding the capability of its POC system being developed for ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Preclinical Development of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 in the Context of an Influenza Vaccine

    SBC: ADJUVANCE TECHNOLOGIES INC.            Topic: NIAID

    Increasingly defined vaccines against infectious diseases are better tolerated but less immunogenicrequiring use of an immunological adjuvant for best effectAdjuvance s semi synthetic saponin adjuvant TiterQuilTQLhas shown remarkable efficacy with a variety of antigens with no detectable reactogenicityWhen combined withof the leading vaccines against influenzaFluzoneFluarix and Flublokstriking aug ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. DNA Based Nanoparticle Platform for HIV Env Presentation

    SBC: PARABON NANOLABS, INC.            Topic: NIAID

    In this projectParabon NanoLabs and The Scripps Research Institute propose to develop and produce an effective HIVvaccine using a structured DNA origami nanocarrier for the targetedcontrolled delivery of a stabilizedtrimeric HIVenvelope glycoproteinEnvwith an integrated adjuvantThe project will begin with the synthesis and characterization of composite nanostructurePV NFLto include development and ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A Liposomal Platform for Spontageous, Particleized Presentation of HIV Trimer Immunogens

    SBC: POP Biotechnologies Inc.            Topic: NIAID

    Over one million Americans andmillion people worldwide are infected with HIVmaking it one of the most pressing public health concerns of our timeUnfortunatelythere are no vaccines available and treatment requires lifelong anti retroviral therapiesThis proposal combines two technologies for the development of a vaccine against HIVEnva novel adjuvantspontaneous nanoliposome antigen particleizationSN ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. FAST-CMV: A Point-of-Care Cytomegalovirus Serodiagnostic and Avidity Assy

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: NIAID

    Congenital cytomegalovirusCMVinfection is the leading cause of permanent disabilitiescognitive impairmentand sensorineural hearing loss to newbornsMaternal infections that occur during pregnancy and symptomatic congenital CMV infections have been correlated with the most severe complicationsClinical trials are currently evaluating safety and immunogenicity of diverse vaccine candidates driven by t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Advanced development of a novel nanoparticle conjugate vaccine for Salmonella Paratyphi A

    SBC: KJ BIOSCIENCES LLC            Topic: NIAID

    Salmonella Paratyphi ASParatyphi Ais a major cause of life threatening enteric feverThere is no vaccine available against this pathogenIn the SBIR phase I studieswe have successfully demonstrated the technical feasibility of a novel nanoparticle conjugate vaccine candidate for SParatyphi AIt is based on O polysaccharideOPSantigen conjugated to a novel and highly advantageous nanoparticle protein c ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government